MRK Stock Recent News
MRK LATEST HEADLINES
DARMSTADT, Germany--(BUSINESS WIRE)--Merck, a leading science and technology company, today announced the discontinuation of the Phase III randomized TrilynX study evaluating xevinapant plus chemoradiotherapy (CRT) in patients with unresected locally advanced squamous cell carcinoma of the head and neck (LA SCCHN). The decision follows a pre-planned interim analysis performed by the study's Independent Data Monitoring Committee, which found that the trial would be unlikely to meet its primary o.
Merck (MRK) closed at $127.99 in the latest trading session, marking a +0.38% move from the prior day.
Pfizer currently dominates the market for pneumococcal vaccines. Merck aims to change that.
The Food and Drug Administration (FDA) has approved Merck's (MRK) new vaccine to protect adults from pneumonia. Yahoo Finance's Anjalee Khemlani reports more on how the vaccine works as the pharmaceutical company awaits the Centers for Disease Control's (CDC) recommendation.
The U.S. Food and Drug Administration (FDA) approved Merck & Co Inc's (NYSE:MRK) next-generation vaccine to protect adults against the pneumococcal disease.
Merck's (MRK) 21-valent pneumococcal conjugate vaccine, Capvaxive/V116, becomes the first PCV specifically designed for adults to be approved by the FDA.
Merck said on Monday the U.S. Food and Drug Administration has approved its next-generation vaccine to protect adults against pneumococcal disease.
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--FDA Approves CAPVAXIVE (Pneumococcal 21-valent Conjugate Vaccine) for Prevention of Invasive Pneumococcal Disease & Pneumococcal Pneumonia in Adults.
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--FDA Approves Merck's KEYTRUDA Plus Chemotherapy as Treatment for Adult Patients With Primary Advanced or Recurrent Endometrial Carcinoma.
The Food and Drug Administration approved Merck's vaccine designed to protect adults from a bacteria known as pneumococcus that can cause serious illnesses and a lung infection called pneumonia. An advisory panel to the Centers for Disease Control and Prevention will meet on June 27 to discuss who should be eligible for the shot, called Capvaxive